Hudson Institute to Present Photosoft at Combio2022
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
HUDSON INSTITUTE TO PRESENT PHOTOSOFTTM AT PRESTIGIOUS COMBIO2022 INDUSTRY
CONFERENCE
MELBOURNE (AUSTRALIA) 27 September 2022: Invion Limited (ASX: IVX) (“Invion” or the
“Company”) wishes to announce that Hudon Institute of Medical Research (Hudson Institute)
is presenting a poster on the PhotosoftTM technology at the prestigious ComBio2022 industry
conference to be held in Melbourne from 27-30th September 2022.
ComBio is the Australian Society for Biochemistry and Molecular Biology’s (ASBMB’s) national
biennial conference, which runs in conjunction with other societies and features world
renowned international speakers.
The poster presentation by Hudson Institute (attached to the end of this announcement)
compares a PhotosoftTM compound with two other chlorin-based photosensitisers including
Talaporfin sodium, which is approved in Japan for the treatment of lung cancer.
The key findings highlighted in the poster found that phyllochlorin sodium – a compound that
belongs to a new group of chlorin-based photosensitisers within the PhotosoftTM technology
suite -– demonstrated the following in vitro and in vivo:
Exhibited rapid cellular uptake and clearance in ovarian cancer lines
Strongly localised to endoplasmic reticulum (ER) upon uptake into cells
Accumulated rapidly and was retained in tumour tissue for at least 48 hours when
injected in vivo (syngeneic mouse model of triple negative breast cancer)
Immediately and efficiently produced reactive oxygen species (ROS) when exposed
to light at 660nm, and thereby cell death in the tumour
Showed low dark toxicity in the absence of light activation and significantly greater
phototoxicity upon illumination when compared with the other two compounds
Hudson Institute’s research offers insight into the development of a novel family of
photosensitisers based on the PhotosoftTM technology and their potential clinical efficacy
and application for Photodynamic Therapies.
This announcement was approved for release by Thian Chew, Chairman of the Board.
____________________________________________
Investor and Media enquiries:
Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com
Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com
About Invion
Invion is a life-science company that is leading the global research and development of the
PhotosoftTM technology for the treatment of a range of cancers, atherosclerosis and infectious
Invion Limited ABN 76 094 730 417
100 Albert Road, South Melbourne, VIC 3205
P: +61 3 9692 7222 W: www.inviongroup.com
ASX ANNOUNCEMENT
diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive
distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in
the Territory), Macau, Taiwan, Japan and South Korea to the PhotosoftTM technology for all
cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding
Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials
are funded by the technology licensor, RMW Cho Group Limited, via an R&D services
agreement with the Company. Invion is listed on the ASX (ASX: IVX).
About Photodynamic Therapy (PDT)
Invion is developing PhotosoftTM technology as a novel next generation Photodynamic
Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and
promote an anti-cancer immune response. Less invasive than surgery and with minimal side
effects, PDT offers an alternative treatment option aimed at achieving complete tumour
regression and long-lasting remission.
Invion Limited ABN 76 094 730 417
100 Albert Road, South Melbourne, VIC 3205
P: +61 3 9692 7222 W: www.inviongroup.com
Identification and characterisation of Phyllochlorin sodium, a novel
chlorin-derived photosensitiser
Yiqian Chen1,2, Laura R Moffitt1,2, Sebastian M. Marcuccio3,4 and Andrew N Stephens1,2
1 Hudson Institute of Medical Research, VIC, Australia
2 Monash University, VIC, Australia
3 Advanced Molecular Technologies, VIC, Australia
4 La Trobe University, VIC, Australia
Phyllochlorin sodium shows enhanced rate
of singlet oxygen production than other
chlorin-derived photosensitisers.
Phyllochlorin sodium demonstrates low
dark toxicity and greater phototoxicity than
other chlorin photosensitisers.
(A)
Singlet oxygen generation
Viability (% of control)
25000
Chlorin e4 sodium
Talaporfin sodium
Phyllochlorin sodium
20000
Phyllochlorin sodium shares spectral
characteristics to other chlorin-derived
photosensitisers.
(A)
Chlorin e4 sodium
Talaporfin sodium
Phyllochlorin sodium
100
80
Chlorin e4 sodium
60
Talaporfin sodium
40
Phyllochlorin sodium
20
1
2
4
6
8
100
Phototoxicity in SKOV3 cell line
10
Viability (% of control)
Time (sec)
Figure 2. Upon illumination at 660 nm, time course of formation
of singlet oxygen as determined by measuring the fluorescence
of the fluorescent probe Singlet Oxygen Sensor Green
(SOSG). The slope of the linear regression curve represents
the rate of the singlet oxygen generation reaction. n=4.
Phyllochlorin sodium accumulates and
releases rapidly in cancer cells in vitro.
Uptake 4h
Uptake 24h
Clearance 1h
Clearance 4h
120
100
80
Chlorin e4 sodium
60
Talaporfin sodium
Phyllochlorin sodium
40
20
0.01
0.1
1
10
100
Photosensitiser (mM)
Figure 6. (A) Dark toxicity (without light activation) and (B)
phototoxicity (exposure to red light of 660 nm) of Phyllochlorin
sodium, Chlorin e4 sodium and Talaporfin sodium in SKOV3
ovarian cancer cells was assessed using AlamarBlue assay.
Viability was expressed as % of untreated controls. n=4.
(A)
Uptake 2h
10
Photosensitiser (mM)
(B)
Chlorin e4 sodium Talaporfin sodium Phyllochlorin sodium
Best-fit values
Slope
1066
736.7
1445
Results:
120
15000
0
Methods:
Phyllochlorin sodium localises to tumours
in vivo.
Clearance 24h
Chlorin e4
sodium
(A)
Talaporfin
sodium
15 min
1h
4h
24 h
48 h
Phyllochlorin
sodium
(B)
Cellular uptake and clearance in SKOV3 cells
Normalized Fluorescence (%)
Phyllochlorin
sodium
absorbance
and
fluorescence spectra and reactive oxygen
species (ROS) production on illumination at 660
nm were compared with two photosensitisers of
Chlorin family, Chlorin e4 sodium and the
clinically
approved
Talaporfin
sodium
(Laserphyrin®, mono-L-aspartyl chlorin e6) in a
cell-free system. In vitro cellular uptake and
clearance were monitored using fluorescence in
ovarian cancer cell lines, with subcellular
localisation
determined
using
confocal
microscopy with specific organelle staining for
endoplasmic reticulum (ER), mitochondria and
lysosome. Cell viability with (for phototoxicity)
and without (for dark-toxicity) exposure to red
light (660 nm) was determined by AlamarBlue
assay. Mice with established primary breast
tumours received Phyllochlorin sodium by
intravenous (IV) injection, oral gavage, or
intratumoral (IT) injection. At pre-determined
intervals post-administration, the localisation of
Phyllochlorin sodium in tumours was quantified
using the IVIS Lumina Imaging System to
provide the average radiant efficiency as a
measure of fluorescence of the tumour area at
each time point.
Dark toxicity in SKOV3 cells
30000
Fluorescence of SOSG (RFU)
Background:
Photodynamic therapy (PDT), combining a
photosensitising compound and light to
generate destructive reactive oxygen species
(ROS), is an effective strategy for tumour tissue
ablation. FDA-approved for the treatment of
several cancer types, a lack of efficacy and
undesirable toxic side effects associated with
many existing photosensitisers has largely
restricted their use to superficial tumours. This
work presents data characterising a new
chlorin-based photosensitiser - Phyllochlorin
sodium - in vitro and in vivo.
120
uptake
(B)
clearance
100
Chlorin e4 sodium
80
Talaporfin sodium
60
Phyllochlorin sodium
40
20
0
12 4
2412 4
24
Time (hour)
Figure 2. (A) Cellular uptake and clearance of Phyllochlorin
sodium, Chlorin e4 sodium and Talaporfin sodium in SKOV3
ovarian cancer cells over time. Images were captured and
analysed using the Cytation 3 Multimode Imager. (B)
Fluorescence intensity was generated from images, and data
were expressed as a percentage of maximum (100%)
fluorescence which was defined at 24 h uptake. n=3.
Upon uptake into cells, Phyllochlorin
sodium strongly co-localises to the ER.
Nucleus
Endoplasmic Reticulum
Phyllochlorin sodium
Merge
Figure 4. Localisation of Phyllochlorin sodium in tumours.
(A) Mice bearing breast tumours received Phyllochlorin sodium
1mg/kg by intravenous (IV), oral gavage or intratumoural (IT)
administration routes. After 15 min, 1 h, 4 h, 24 h and 48 h,
Phyllochlorin sodium fluorescence in tumour was imaged using
the IVIS Lumina in vivo Imaging System. (B) Quantitative
average radiant efficiency of the tumour area was calculated
and corrected for the vehicle control. n=3/group.
Conclusions:
(B)
Talaporfin sodium
Phyllochlorin sodium
40
20
0
350
400
450
500
550
600
Wavelength (nm)
650
700
750
Normalized Fluorescence (%)
Normalized Absorbance (%)
Chlorin e4 sodium
60
Mitochondria
Phyllochlorin sodium
Merge
Nucleus
Lysosome
Phyllochlorin sodium
Merge
Fluorescence spectra in DMSO
Absorption spectra in DMSO
100
80
Nucleus
100
80
Chlorin e4 sodium
Talaporfin sodium
60
Phyllochlorin sodium
40
20
0
600
620
640
660
680
700
Wavelength (nm)
Figure 1. (A) Chemical structure of Chlorin e4 sodium,
Talaporfin sodium and Phyllochlorin sodium. (B) Absorption
and fluorescence spectra of Chlorin e4 sodium, Talaporfin
sodium and Phyllochlorin sodium in DMSO. Absorbance was
scanned 350-750 nm in 2 nm increments. Fluorescence
emission with excitation at 400 nm was scanned 600-700 nm in
2 nm increments.
Figure 3. Subcellular localisation of Phyllochlorin sodium in
SKOV3 ovarian cancer cells. Cells treated with Phyllochlorin
sodium were stained with ER-Tracker Green, MitoTracker
Green or LysoTracker Green and cell nuclei counterstained
with Hoechst 33342. Images were captured using a 100x oil
objective lens on confocal microscope. Scale bars: 10 μm.
Compared to other Chlorin photosensitisers,
Phyllochlorin sodium demonstrated:
• Similar spectral properties;
• Substantially enhanced ROS production and
phototoxicity, with an increased therapeutic
window;
• Excellent localisation and retention to tumour
tissue in vivo.
Our study offers insight into the development of
a novel family of photosensitisers and their
potential clinical efficacy and application for
PDT.
Acknowledgments:
We acknowledge Invion Limited and RMW Cho Group.
Share your feedback
Discover